Erasca (ERAS) EPS (Weighted Average and Diluted) (2021 - 2026)
Erasca (ERAS) reported EPS (Weighted Average and Diluted) of -$0.6 for Q1 2026, down 445.45% on a YoY basis from $0.17 in Q1 2025, and down 500.0% quarter-over-quarter from -$0.1 in Q4 2025.
Erasca (ERAS) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Erasca has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.6 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 445.45% year-over-year to -$0.6; the trailing twelve-month figure through Mar 2026 stood at -$0.93 (down 55.0% YoY), and the FY2025 full-year result was -$0.44, up 36.23% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.6, down from -$0.1 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.09 in Q4 2024, with the low at -$1.09 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.27 across 5 years, with a median of -$0.21 in 2023.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) sank 2280.0% — and 2023, when it jumped 82.57%.
- Erasca's EPS (Weighted Average and Diluted) stood at -$1.09 in 2022, then jumped by 82.57% to -$0.19 in 2023, then surged by 52.63% to -$0.09 in 2024, then declined by 11.11% to -$0.1 in 2025, then plunged by 500.0% to -$0.6 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.6 (Q1 2026), -$0.1 (Q4 2025), and -$0.11 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | -0.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.60 |
| Dec 31, 2025 | -0.10 |
| Sep 30, 2025 | -0.11 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.11 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.11 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.23 |
| Dec 31, 2023 | -0.19 |
| Sep 30, 2023 | -0.20 |
| Jun 30, 2023 | -0.21 |
| Mar 31, 2023 | -0.22 |
| Dec 31, 2022 | -1.09 |
| Sep 30, 2022 | -0.29 |
| Jun 30, 2022 | -0.30 |
| Mar 31, 2022 | -0.31 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | -0.46 |
| Jun 30, 2021 | -1.20 |